Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0024623 (
gastric cancer
)
36,219
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The results obtained with a three-fold association of drugs (
VCR
, 5Fu, MeCCNU) in the treatment of 68 patients suffering from advanced carcinoma of the gastroenteric system followed up over an approximately four year period at the Savona Oncology Centre are reported. The percentage of positive responses (CR + PR) was 75% for carcinoma of the colon-rectum and 44.4% for
stomach cancer
. The results obtained in intestinal carcinoma proved more satisfactory than those reported in the literature. This could be attributed to the contemporaneous use of Corynebacterium parvum which boosts the immunitary state and so enhances the defences of the host organism, making it more sensitive to polychemotherapy. In the light of this hypothesis, stress is laid on the need to use an immunochemotherapy approach for the treatment of advanced carcinoma of the gastroenteric apparatus.
...
PMID:[Immunochemotherapeutic treatment of gastrointestinal neoplasms]. 730 Nov 83
AIM:To compare the expression level of Fas gene and Bcl-2 gene in
gastric cancer
cells SGC7901 and
gastric cancer
MDR (multidrug resistant) cells SGC7901/
VCR
,to transduce Fas cDNA and Bcl-2 antisense nucleic acid into SGC7901/
VCR
cells respectively, and to observe the expression of two genes in transfectants and non-transfectants as well as their drug sensitivity.METHODS:Eukaryotic expression vector pBK-Fas cDNA and pDOR-anti Bcl-2 were constructed and transfected into SGC7901/
VCR
cells by lipofectamine,respectively.Northern blot and Western blot were used to detect the expression of mRNA and protein in SGC7901/
VCR
and SGC7901 cells and transfectants, and drug sensitivity of transfectants for
VCR
, CDDP and 5-FU was analyzed with MTT assay.RESULTS:After gene transfection, 80 for Fas and 120 for antisense Bcl-2 drug-resistant clones were selected from 2 X10(5) cells, transfection rate being 0.04% and 0.06%. Two clones of SGC7901 Fas/
VCR
cells and SGC7901 anti Bcl-2/
VCR
cells were randomly selected for further incubation. Hybridization results showed that the expression level of Fas mRNA and protein in SGC7901/
VCR
cells was much lower,but that of Bcl-2 mRNA and protein was higher than that in SGC7901 cells. The expression of Fas mRNA and protein in SGC7901 Fas/
VCR
cells was higher,and of Bcl-2 mRNA and protein was lower in SGC7901 anti Bcl-2/
VCR
cells than that in non-transfectants. MTT assay showed that transfectants were more sensitive to
VCR
, CDDP, 5-FU than non-transfectants. CONCLUSION:Bcl-2 gene displayed high expression while Fas gene had low expression in drug resistant
gastric cancer
cells. Expression of Bcl-2 protein was effectively blocked in SGC7901 anti Bcl-2/
VCR
cells by gene transfection. In contrast, the expression of Fas mRNA and protein in SGC7901 Fas/
VCR
cells increased. Fas gene and Bcl-2 antisense nucleic acid transfection sensitized drug resistant
gastric cancer
cells to chemotherapeutic drugs. These results suggest cell apoptosis plays an important role in the mechanism of MDR, and enhancing apoptosis might reverse MDR.
...
PMID:Transduction of Fas gene or Bcl-2 antisense RNA sensitizes cultured drug resistant gastric cancer cells to chemotherapeutic drugs. 1181 36
AIM:To further investigate the effect of cyclin D1 on the biologic behavior of cancer cells and its potential role in gene therapy of tumor.METHODS:A cyclin D1 subcloning plasmid termed BKSD1 was constructed by subcloning the human cyclin D1 cDNA into Bluescript-KS, a plasmid vector with a pair of T7 and T3 promoters, with recombinant DNA technology of molecular biology. So,it is easy to generate digoxigenin (DIG)-labeled RNA probes of antisense and sense to cyclin D1 using RKSD1 as a template vector. PDORD1AS, an eukaryotic expression vector containing the full-length human cyclin D1 cDNA in its antisense orientation cloned into the retroviral vector pDOR-neo, was successfully constructed with BKSD1 to change restriction sites. A
gastric cancer
cell line, SGC7901/
VCR
, was transfected with pDORD1AS by Lipofect Amine-mediated introduction and a subline termed SGC7901/VCRD1AS, which had stable overexpression of antisense RNA to cyclin D1, was obtained by selection in G418. The subline, control subline transfected pDOR-neo and SGC7901/
VCR
were evaluated by methods of immunohistochemistry, flow cytometry, molecular hybridization, morphology and cell biology.RESULTS:Compared with control cell lines, SGC7901/VCRD1AS had a reduced expression of cyclin D1 (inhibition rate was about 36%), increased cell size and cytoplasm to nucleus ratio, increased doubling time (42.2h to 26.8h and 26.4h), decreased saturation density (18.9X10(4) to 4.8X10(5) and 4.8X10(5)), increased percentage of cells in the G(1)/G(0) phase (80.9%-64.6% and 63.8%), reacquired serum dependence, and a loss of tumorigenicity in nude mice (0/4 to 4/4 and 4/4).CONCLUSION: Stable overexpression of antisense RNA to cyclin D1 can reverse the transformed phenotype of human
gastric cancer
cells and may provide an approach of gene therapy for
gastric cancer
.
...
PMID:Antisense to cyclin D1 reverses the transformed phenotype of human gastric cancer cells. 1181 76
AIM:To observe the drug sensitizing effect and related mechanisms of fas gene transduction on human drug-resistant
gastric cancer
cell SGC7901/
VCR
(resistant to Vincristine).METHODS:The cell cycle alteration was observed by FACS. The sensitivity of
gastric cancer
cells to apoptosis was determined by in vitro apoptosis assay. The drug sensitization of cells to several anti-tumor drugs was observed by MTT assay. Immunochemical method was used to show expression of P-gp and Topo II in
gastric cancer
cells.RESULTS:Comparing to SGC7901 and pBK-SGC7901/
VCR
, fas-SGC7901/
VCR
showed decreasing G2 cells and increasing S cells, the G2 phase fraction of pBK-SGC7901/
VCR
was about 3.0 times that of fas -SGC7901/
VCR
but S phase fraction of fas -SGC7901/
VCR
was about 1.9 times that of pBK-SGC7901/
VCR
, indicating S phase arrest of fas-SGC7901/
VCR
. FACS also suggested apoptosis of fas-SGC7901/
VCR
.fas-SGC7901/
VCR
was more sensitive to apoptosis inducing agent VM-26 than pBK-SGC7901/
VCR
. MTT assay showed increased sensitization of fas-SGC7901/
VCR
to DDP, MMC and 5-FU, but same sensitization to
VCR
according to pBK-SGC7901/
VCR
. SGC7901, PBK-SGC7901/
VCR
and fas -SGC7901/
VCR
had positively stained Topo II equally. P-gp staining in pBK-SGC7901/
VCR
was stronger than in SGC7901, but there was little staining of P-gp in fas-SGC7901/
VCR
.CONCLUSION:fas gene transduction could reverse the MDR of human drug-resistant
gastric cancer
cell SGC7901/
VCR
to a degree, possibly because of higher sensitization to apoptosis and decreased expression of P-gp.
...
PMID:Suppression of P-gp induced multiple drug resistance in a drug resistant gastric cancer cell line by overexpression of Fas. 1181 71
ZNRD1, a new zinc ribbon gene, has been previously identified as an upregulated gene in a multidrug-resistant
gastric cancer
cell line SGC7901/
VCR
comparing to its parental cell SGC7901 by subtractive hybridization and RT-PCR. The antisense nucleic acid for ZNRD1 could enhance adriamycin accumulation in SGC7901/
VCR
cells and sensitize SGC7901/
VCR
cells to vincristine. The present study aims to explore the role of ZNRD1 in multidrug resistance in
gastric cancer
cells. Upregulation of ZNRD1 protein in SGC7901/
VCR
cells was confirmed by Western blot and immunocytochmical staining. ZNRD1 was genetically overexpressed in SGC7901 cells by gene transfection. It was found that overexpression of ZNRD1 could sensitize SGC7901 cells to P-glycoprotein (P-gp)-related anticancer drugs (vincristine, adriamycin, etoposide) but not to P-gp-nonrelated drugs (5-fluorouracil and cisplatin), which was accompanied with significantly decreased adriamycin accumulation and retention and increased adriamycin releasing in SGC7901 cells. Verapamil, an inhibitor for P-gp, could reverse the effects of ZNRD1 on drug sensitivity and drug accumulation in SGC7901 cells to a great extent. Western blot and Northern blot revealed that overexpression of ZNRD1 could upregulate P-gp at both protein and mRNA levels. Together, these results suggest that overexpression of ZNRD1 could promote multidrug-resistant phenotype of
gastric cancer
cells through upregulation of P-gp.
...
PMID:Overexpression of ZNRD1 promotes multidrug-resistant phenotype of gastric cancer cells through upregulation of P-glycoprotein. 1497 23
We have previously identified tumor susceptibility gene101 (TSG101), overexpressed in vincristine-resistant human gastric adenocarcinoma cell line SGC7901/
VCR
using a modified subtractive hybridization method and Western blot. In the present study, we constructed two siRNA eukaryotic expression vectors of TSG101 and transfected them into SGC7901/
VCR
cells to examine whether the down-regulation of TSG101 increased cell sensitivity towards chemotherapeutic drugs. After transfection, the expression of TSG101 was dramatically decreased in TSG101 siRNA transfectants compared with that in parental cells and empty vector control cells. The down-regulation of TSG101 could significantly enhance the sensitivity of SGC7901/
VCR
cells to vincristine and adriamycin. The capacity of cells to efflux adriamycin markedly decreased in TSG101 siRNA transfectants. These observations suggested that the siRNA constructs of TSG101 we made could effectively down-regulate the expression of TSG101 and reverse the resistant phenotype of
gastric cancer
cells. The preliminary study suggested that TSG101 might play an important role in multidrug resistance of gastric carcinoma.
...
PMID:Reversal of multidrug resistance of gastric cancer cells by downregulation of TSG101 with TSG101siRNA. 1519 57
Ribosomal proteins (RP) S13 and RPL23 were previously identified as two upregulated genes in a multidrug-resistant
gastric cancer
cell line SGC7901/
VCR
compared to its parental cell SGC7901 by differential display PCR. The aim of this study was to explore the roles of RPS13 and RPL23 in multidrug resistance (MDR) in
gastric cancer
cells. RPS13 and RPL23 were genetically overexpressed in SGC7901 cells, respectively. Either RPS13 or RPL23 enhanced resistance of SGC7901 cells to vincristine, adriamycin, and 5-fludrouracil. RPL23 also enhanced resistance of SGC7901 cells to cisplatin. Overexpression of either RPS13 or RPL23 did not alter the population doubling time, [3H]leucine incorporation, and intracellular adriamycin accumulation of SGC7901 cells. However, either RPS13 or RPL23 could protect SGC7901 cells from undergoing vincristine-induced apoptosis. Western blot analysis revealed that both RPS13 and RPL23 significantly increased the expression level of Bcl-2 and Bcl-2/Bax ratio in SGC7901 cells. In addition, overexpression of RPL23 enhanced glutathione S-transferase (GST) activity and intracellular glutathione content in SGC7901 cells. Together, this work demonstrates that either RPS13 or RPL23 can promote MDR in
gastric cancer
cells by suppressing drug-induced apoptosis, and that RPL23 may also promote MDR in
gastric cancer
cells through regulation of glutathione S-transferase-mediated drug-detoxifying system.
...
PMID:Ribosomal proteins S13 and L23 promote multidrug resistance in gastric cancer cells by suppressing drug-induced apoptosis. 1514 63
The over-expression of a new zinc ribbon (ZNRD1) gene has been shown previously to promote a multidrug-resistant phenotype in
gastric cancer
cells through the up-regulation of permeability-glycoprotein (P-gp). In the present study, siRNA eukaryotic expression vectors of ZNRD1 are constructed and transfected into SGC7901/
VCR
cells to examine whether or not down-regulation of ZNRD1 increases cell sensitivity towards chemotherapeutic drugs. After transfection, ZNRD1 expression decreased dramatically in ZNRD1 siRNA transfectants compared with that in parental cells and empty vector control cells. Down-regulation of ZNRD1 significantly enhanced the sensitivity of SGC7901/
VCR
cells to vincristine, adriamycin and etoposide, but not to 5-fluorouracil and cisplatin. Cell capacity to efflux adriamycin decreased markedly in ZNRD1 siRNA transfectants, and correlation between ZNRD1 down-regulation and increased multidrug resistance 1 (MDR1) gene transcriptional activity was observed. These results suggest that the ZNRD1 siRNA constructs down-regulate the expression of ZNRD1 effectively and reverse the resistant phenotype of
gastric cancer
cells. Furthermore, ZNRD1 might influence transcription of the MDR1 gene and thus play an important role in multidrug resistance in gastric carcinoma.
...
PMID:Reversal of multidrug resistance of gastric cancer cells by down-regulation of ZNRD1 with ZNRD1 siRNA. 1564 14
Mad2beta is an alternative splicing variant of spindle checkpoint gene mad2, which was previously found by us and was related to the drug resistance in
gastric cancer
cells. In this paper, we explored the molecular mechanisms that Mad2beta variant promoted the formation of multidrug resistance in
gastric cancer
cells. We found that Mad2beta variant was detected only in the two human drug resistant
gastric cancer
cell sublines SGC7901/
VCR
and SGC7901/ADR, and it did not appear in its parental cell line SGC7901 and other detected
gastric cancer
cell lines. Expressions of Mad2 mRNA and protein in SGC7901 cells transfected with Mad2beta, SGC7901/
VCR
and SGC7901/ADR were significantly lower than that in SGC7901 cells. Moreover, SGC7901 cells overexpressing Mad2beta variant became more resistant to adriamycin, vincristine and mitomycin by abrogating mitotic arrest and apoptosis. This suggests that expression of Mad2beta variant decreases the relative expression of efficient MAD2, which may help
gastric cancer
cells to develop the phenotype of multidrug resistance.
...
PMID:Mad2beta, an alternative variant of Mad2 reducing mitotic arrest and apoptosis induced by adriamycin in gastric cancer cells. 1621 81
Voltage-gated potassium (Kv) channels have been reported to be involved in the proliferation of many types of cells, including tumor cells. The overexpression of the Kv channels and related channel activity are involved in the neoplastic process. Our previous study has shown the existence of delayed rectifier potassium (I(K)) current in
gastric cancer
cells SGC7901. However, the expression and function of most delayed rectifier potassium (K(D)) channel subunits in
gastric cancer
cells are not completely resolved. Here we examine expression of K(D) channel subunits in Kv1-Kv3 families in immortalized gastric epithelial cells GES and various
gastric cancer
cells (including AGS, KATOIII, MKN28, MKN45, MGC803, SGC7901, SGC7901/ADR and SGC7901/
VCR
), and their roles in cell proliferation. RT-PCR analysis reveals that all cell lines examined express Kv1.3, Kv1.5, Kv1.6, Kv2.1 and Kv2.2. However, Kv1.2 and Kv3.2 genes are barely detectable in any given cancer cell lines. Kv1.5 protein, high mRNA levels in all cell lines examined, is also expressed in some cancer cells lines and more frequently detected in
gastric cancer
tissues. Downregulation of the expression of Kv1.5 in SGC7901 with RNA interference significantly inhibited the proliferation and tumorigenicity of SGC7901 cells. Moreover, in Ca(2+)-containing rather than Ca(2+)-free medium, KCl (50mM) stimulated a rapid increase in the concentration of cytosolic calcium in empty vector transfected cells that was blocked by verapamil. Likewise, decrease the expression of Kv1.5 with short interfering RNA also blocked the depolarization-induced influx of Ca(2+). This finding suggests that more than one kind of K(D) channel subunits are expressed in various
gastric cancer
cell lines. Kv1.5 may be involved in tumor cells proliferation by controlling Ca(2+) entry, and the interference of K(D) channels expression and/or activity could provide a novel strategy to reverse the malignant phenotype of
gastric cancer
cells.
...
PMID:Expression of delayed rectifier potassium channels and their possible roles in proliferation of human gastric cancer cells. 1625 62
1
2
3
4
Next >>